Gefitinib is an EGFR/tyrosine kinase inhibitor that showed early promise in the treatment of VS in vitro45; a retrospective human study of its analog, erlotinib, in NF2 patients did not result in a measurable reduction in tumor volume overall, though three patients reported hearing improvement46. The gene discussed is NF2; the disease is neoplasm.